{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-26-000050","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2026-06-05T20:29:35+00:00","discovered_at":"2026-06-05T20:31:00.470814+00:00","generated_at":"2026-06-05T20:34:49.400539+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"NovoCure shareholders elect 11 directors, approve incentive plan by slim margin at 2026 AGM","bullets":["All 11 director nominees elected with 79.5M to 82.5M for votes; term expires 2027.","Ratified Kost Forer Gabbay & Kasierer as independent auditor for FY2026: 91.4M for, 2.3M against.","Advisory vote to approve executive compensation passed: 75.4M for vs 7.4M against.","Amended & Restated 2024 Omnibus Incentive Plan approved by narrow margin: 41.68M for, 41.16M against (plus 10.87M broker non-votes).","93.8M shares represented (81% of entitled) at the June 3, 2026 annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-26-000050","json":"https://secwatch.observer/filing/0001645113-26-000050.json","markdown":"https://secwatch.observer/filing/0001645113-26-000050.md","text":"https://secwatch.observer/filing/0001645113-26-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000050/0001645113-26-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000050/nvcr-20260603.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T20:34:49.400539+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6eae985fec45f99444b5e7ccab7a8af468b7acf4","claim":"NovoCure Ltd shareholders approved Ratification of Independent Registered Public Accounting Firm at the 2026-12-31 meeting.","evidence_excerpt":"2. Ratification of Independent Registered Public Accounting Firm . The proposal to approve and ratify the appointment, by the Audit Committee of the Company’s Board of Directors, of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the auditor and independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026 was approved as an ordinary resolution based upon the following votes: For Against Abstain 91,436,910 2,337,255 52,565","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000050/0001645113-26-000050-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-12-31"}],"fact_type":"shareholder_vote"},{"claim_id":"7fbde5297e26dfca72cb213c07443b80526990c4","claim":"NovoCure Ltd shareholders approved Election of Directors.","evidence_excerpt":"1. Election of Directors . The eleven nominees for election to the Company’s Board of Directors were elected as directors to hold office until the Company’s 2027 Annual Meeting of Shareholders or until their successors are duly elected and qualified or until their offices are vacated, based upon the following votes: For Against Abstain Broker non-votes Asaf Danziger 81,489,609 1,388,512 74,479 10,874,130 William Doyle 80,241,009 2,664,190 47,401 10,874,130 Jeryl Hilleman 81,547,820 1,293,373 111,407 10,874,130 David Hung 80,768,325 2,039,529 144,746 10,874,130 Frank Leonard 82,547,254 356,494 48,852 10,874,130 Kinyip Gabriel Leung 79,455,754 3,370,420 126,426 10,874,130 Martin Madden 81,360,641 1,461,539 130,420 10,874,130 Allyson Ocean 81,178,295 1,666,945 107,360 10,874,130 Timothy Scannell 81,540,531 1,292,301 119,768 10,874,130 Kristin Stafford 81,584,398 1,272,045 96,157 10,874,130 William Vernon 81,349,410 1,483,356 119,834 10,874,130","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000050/0001645113-26-000050-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"dd614cc02c2f708ce0cd36896249684791ea733d","claim":"NovoCure Ltd shareholders approved Approval of the Company's Amended and Restated 2024 Omnibus Incentive Plan.","evidence_excerpt":"4. Approval of the Company's Amended and Restated 2024 Omnibus Incentive Plan . The proposal to approve the Company's Amended and Restated 2024 Omnibus Incentive Plan was approved as an ordinary resolution based upon the following votes: For Against Abstain Broker non-votes 41,680,622 41,161,139 110,839 10,874,130","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000050/0001645113-26-000050-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"f329e680ac40deb7eee061e75a4e7864352cf450","claim":"NovoCure Ltd shareholders approved Non-binding advisory vote to approve executive compensation.","evidence_excerpt":"3. Approval of a non-binding advisory vote to approve executive compensation . The proposal to approve executive compensation on a non-binding advisory basis was approved as an ordinary resolution based upon the following votes: For Against Abstain Broker non-votes 75,392,168 7,422,876 137,556 10,874,130","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000050/0001645113-26-000050-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}